CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patients – News-Medical.net
News-Medical.net |
CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patients
News-Medical.net In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin’s lymphoma (NHL) patients. Results from a … Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphomaHealio Phase 2 CAR–T study reports significant remission rates at 15-month follow upMedical Xpress New Data for FDA-Approved CAR T Therapy Show Significant …Markets Insider OncLive all 4 news articles » |
|
Drug improves disease-free, overall survival after hematopoietic stem cell transplants
News-Medical.net Results from a phase 2 clinical trial, presented by Seattle Children’s Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft … |
The Times |
Scientists attempt to cure blindness with gene therapy
The Times Irish scientists are attempting to cure one of the most common forms of blindness through gene therapy. Retinitis pigmentosa, which affects about 1,500 people in Ireland, is caused by a faulty gene which causes the light-sensitive retina in the eye to … Irish scientists using ‘Trojan horse’ gene to fight inherited blindnessIndependent.ie |